Target Price | $487.56 |
Price | $416.81 |
Potential | 16.97% |
Number of Estimates | 29 |
29 Analysts have issued a price target Vertex Pharmaceuticals 2026 . The average Vertex Pharmaceuticals target price is $487.56. This is 16.97% higher than the current stock price. The highest price target is $655.20 57.19% , the lowest is $333.30 20.04% . | |
A rating was issued by 39 analysts: 25 Analysts recommend Vertex Pharmaceuticals to buy, 13 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Vertex Pharmaceuticals stock has an average upside potential 2026 of 16.97% . Most analysts recommend the Vertex Pharmaceuticals stock at Purchase. |
35 Analysts have issued a sales forecast Vertex Pharmaceuticals 2025 . The average Vertex Pharmaceuticals sales estimate is $12.2b . This is 7.05% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $12.7b 11.58% , the lowest is $11.6b 1.60% .
This results in the following potential growth metrics:
2024 | $11.0b | 11.66% |
---|---|---|
2025 | $12.2b | 10.92% |
2026 | $13.4b | 9.55% |
2027 | $14.6b | 9.03% |
2028 | $15.9b | 8.97% |
2029 | $17.5b | 10.29% |
2030 | $19.2b | 9.18% |
2031 | $19.9b | 3.93% |
2032 | $21.5b | 7.91% |
14 Analysts have issued an Vertex Pharmaceuticals EBITDA forecast 2025. The average Vertex Pharmaceuticals EBITDA estimate is $5.5b . This is 19.82% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $6.1b 32.58% , the lowest is $4.5b 2.57% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | $4.6b | 1.37% |
---|---|---|
2025 | $5.5b | 20.45% |
2026 | $6.6b | 19.72% |
2027 | $7.3b | 9.64% |
2028 | $7.5b | 3.08% |
2029 | $8.2b | 8.72% |
2030 | $8.9b | 8.72% |
2031 | $9.5b | 7.04% |
2032 | $11.3b | 19.21% |
2024 | 41.77% | 9.21% |
---|---|---|
2025 | 45.35% | 8.58% |
2026 | 49.56% | 9.28% |
2027 | 49.84% | 0.56% |
2028 | 47.15% | 5.40% |
2029 | 46.48% | 1.42% |
2030 | 46.28% | 0.43% |
2031 | 47.66% | 2.98% |
2032 | 52.66% | 10.49% |
36 Vertex Pharmaceuticals Analysts have issued a net profit forecast 2025. The average Vertex Pharmaceuticals net profit estimate is $4.7b . This is 29.69% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $5.1b 39.31% , the lowest is $4.3b 17.18% .
This results in the following potential growth metrics and future Net Margins:
2024 | $-536m | 114.80% |
---|---|---|
2025 | $4.7b | 980.78% |
2026 | $5.3b | 12.95% |
2027 | $5.9b | 9.93% |
2028 | $6.5b | 10.35% |
2029 | $7.3b | 13.43% |
2030 | $7.9b | 7.97% |
2031 | $8.6b | 8.40% |
2032 | $9.6b | 12.43% |
2024 | -4.86% | 113.25% |
---|---|---|
2025 | 38.59% | 894.00% |
2026 | 39.79% | 3.11% |
2027 | 40.12% | 0.83% |
2028 | 40.62% | 1.25% |
2029 | 41.78% | 2.86% |
2030 | 41.32% | 1.10% |
2031 | 43.10% | 4.31% |
2032 | 44.91% | 4.20% |
36 Analysts have issued a Vertex Pharmaceuticals forecast for earnings per share. The average Vertex Pharmaceuticals EPS is $18.41 . This is 31.13% higher than earnings per share in the financial year 2024. The highest EPS forecast is $19.77 40.81% , the lowest is $16.63 18.45% .
This results in the following potential growth metrics and future valuations:
2024 | $-2.08 | 114.97% |
---|---|---|
2025 | $18.41 | 985.10% |
2026 | $20.79 | 12.93% |
2027 | $22.85 | 9.91% |
2028 | $25.22 | 10.37% |
2029 | $28.60 | 13.40% |
2030 | $30.88 | 7.97% |
2031 | $33.48 | 8.42% |
2032 | $37.64 | 12.43% |
Current | 29.10 | 111.06% |
---|---|---|
2025 | 22.20 | 23.72% |
2026 | 19.65 | 11.49% |
2027 | 17.88 | 9.01% |
2028 | 16.20 | 9.40% |
2029 | 14.28 | 11.85% |
2030 | 13.23 | 7.35% |
2031 | 12.20 | 7.79% |
2032 | 10.86 | 10.98% |
Based on analysts' sales estimates for 2025, the Vertex Pharmaceuticals stock is valued at an EV/Sales of 8.05 and an P/S ratio of 8.57 .
This results in the following potential growth metrics and future valuations:
Current | 8.62 | 22.20% |
---|---|---|
2025 | 8.05 | 6.63% |
2026 | 7.35 | 8.71% |
2027 | 6.74 | 8.28% |
2028 | 6.18 | 8.23% |
2029 | 5.61 | 9.33% |
2030 | 5.14 | 8.41% |
2031 | 4.94 | 3.78% |
2032 | 4.58 | 7.33% |
Current | 9.17 | 21.47% |
---|---|---|
2025 | 8.57 | 6.59% |
2026 | 7.82 | 8.71% |
2027 | 7.18 | 8.28% |
2028 | 6.58 | 8.23% |
2029 | 5.97 | 9.33% |
2030 | 5.47 | 8.41% |
2031 | 5.26 | 3.78% |
2032 | 4.88 | 7.33% |
Vertex Pharmaceuticals...
Analyst | Rating | Action | Date |
---|---|---|---|
Morgan Stanley |
Equal-Weight
➜
Equal-Weight
|
Unchanged | Oct 10 2025 |
JP Morgan |
Overweight
➜
Overweight
|
Unchanged | Oct 08 2025 |
Citigroup |
Buy
➜
Buy
|
Unchanged | Oct 02 2025 |
Leerink Partners |
Market Perform
➜
Outperform
|
Upgrade | Sep 25 2025 |
Evercore ISI Group |
Outperform
➜
Outperform
|
Unchanged | Sep 11 2025 |
Raymond James |
➜
Market Perform
|
Initiated | Sep 03 2025 |
Guggenheim |
Buy
➜
Buy
|
Unchanged | Aug 06 2025 |
Analyst Rating | Date |
---|---|
Unchanged
Morgan Stanley:
Equal-Weight
➜
Equal-Weight
|
Oct 10 2025 |
Unchanged
JP Morgan:
Overweight
➜
Overweight
|
Oct 08 2025 |
Unchanged
Citigroup:
Buy
➜
Buy
|
Oct 02 2025 |
Upgrade
Leerink Partners:
Market Perform
➜
Outperform
|
Sep 25 2025 |
Unchanged
Evercore ISI Group:
Outperform
➜
Outperform
|
Sep 11 2025 |
Initiated
Raymond James:
➜
Market Perform
|
Sep 03 2025 |
Unchanged
Guggenheim:
Buy
➜
Buy
|
Aug 06 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.